Canadian urological association

McMaster Institute of Urology at St. Published: Robotic-assisted laparoscopic pyeloplasty for ureteropelvic junction obstruction A retrospective review of a high-volume Canadian center Michael Ordon, canadian urological association, Aren Mnatzakanian, Melody Djuimo, R.

The Canadian Urological Association CUA does not provide professional medical advice, diagnosis or treatment and cannot respond to requests for direct feedback, specific patient information or physician referrals. You should first always seek the advice of your urologist, physician and other qualified health provider with any questions regarding your medical condition. The contents of the CUA Website such as text, graphics, images, and other content are for informational purposes only. Never disregard professional medical advice or delay in seeking it because of something you have read on the CUA website. For comments or information, email Corporate. Privacy Policy. Upcoming Events.

Canadian urological association

Federal government websites often end in. The site is secure. Prostate cancer remains the most commonly diagnosed non-cutaneous malignancy among Canadian men and is the third leading cause of cancer-related death. In , an estimated 21 men were diagnosed with prostate cancer and men died from the disease; 1 however, prostate cancer is a heterogeneous disease with a clinical course ranging from indolent to life-threatening. Identifying and treating men with clinically significant prostate cancer while avoiding the over-diagnosis and over-treatment of indolent disease remains a significant challenge. Several professional associations have developed guidelines on prostate cancer screening and early diagnosis, but there are conflicting recommendations on how best to approach these issues. With recent updates from several large, randomized, prospective trials, as well as the emergence of several new diagnostic tests, the Canadian Urological Association CUA has developed these evidence-based recommendations to guide clinicians on prostate cancer screening and early diagnosis for Canadian men. The aim of these recommendations is to provide guidance on the current best prostate cancer screening and early diagnosis practices and to provide information on new and emerging diagnostic modalities. In order to develop these recommendations, the following questions related to prostate cancer screening and diagnosis were defined, a priori, to guide the specific literature searches and evidence synthesis:. The aim of answering the first four questions is to provide guidance on prostate cancer screening in general. The aim of the fifth question is to provide information on additional available tests. Therefore, a different search strategy was used for these questions. For the first four questions, we employed a two-step approach in order to synthesize the best available evidence to develop these recommendations. First, recognizing that several other professional organizations have developed evidence-based guidelines on prostate cancer screening and diagnosis, a complete bibliographic review of existing guidelines on prostate cancer screening and diagnosis was performed. Studies related to questions 1 — 4 were reviewed at full length.

Bruno Laroche Canadian urological association Several professional associations have developed guidelines on prostate cancer screening and early diagnosis, but there are conflicting recommendations on how best to approach these issues. Focal therapy options for treating prostate cancer were more available in the Prairies.

Full-length guidelines are reserved for broader topics that require more comprehensive exploration. BPRs provide a more focused, concise summary of the best evidence available on common urological topics to help guide management decisions. Both formats have undergone official CUA guideline approval process. Reproduction of any part of the published CUA guidelines, consensus statements, and best practice reports requires the express written consent of the Canadian Urological Association CUA. McMaster Institute of Urology at St. Treatment of bladder dysfunction in children, February Male urethral stricture, October

The Canadian Urological Association CUA does not provide professional medical advice, diagnosis or treatment and cannot respond to requests for direct feedback, specific patient information or physician referrals. You should first always seek the advice of your urologist, physician and other qualified health provider with any questions regarding your medical condition. The contents of the CUA Website such as text, graphics, images, and other content are for informational purposes only. Never disregard professional medical advice or delay in seeking it because of something you have read on the CUA website. For comments or information, email Corporate.

Canadian urological association

Federal government websites often end in. The site is secure. Preview improvements coming to the PMC website in October Learn More or Try it out now.

Sketcher deluxe walker

In the six nomograms with adequate validation across several study populations, the discrimination properties for prostate cancer detection were moderate AUC 0. Screening for prostate cancer at low PSA range: The impact of digital rectal examination on tumor incidence and tumor characteristics. Violette , 6, 7 Rodney H. This recommendation places: — Relatively low value on a small and uncertain potential reduction — In prostate cancer mortality — Relatively higher value on the risk of a false-positive result, unnecessary biopsies, over-diagnosis of prostate cancer, and harms associated with unnecessary treatment Therefore: — Risks and benefits of PSA screening and its potential consequences should be discussed with each patient in the context of his preferences — Men who place a high value on a small potential reduction in mortality and are less concerned with undesirable consequences may choose to be screened. Influence of blood prostate-specific antigen levels at age 60 on benefits and harms of prostate cancer screening: Population-based cohort study. BMC Med. Reasons cited included an inability to find a suitable recruit, lack of interest among recruits in the practice location, lack of adequate hospital resources, and failure of cooperation with hospital administration. A four-kallikrein panel predicts prostate cancer in men with recent screening: Data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam. Adjunctive strategies for improving prostate cancer early diagnosis The past two decades have seen the development or evaluation of several potential adjunctive measures that may increase the benefits or reduce the harms associated with screening in addition to PSA. Appendix available at cuaj. Int J Market Res. J Urol.

Federal government websites often end in.

To that end, a census was developed and circulated to the CUA membership. A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer. Appendix available at cuaj. Do prostate cancer risk models improve the predictive accuracy of PSA screening? Prostate cancer screening pathway. Transl Res. Percent free PSA The measurement of percent free PSA has been studied as a risk-stratifying tool aimed at distinguishing men at risk from prostate cancer vs. The decision to proceed with prostate biopsy should take into account several factors, including PSA level, results from adjunct tests or risk calculators, competing comorbidities, and patient preferences. Age- and race-specific reference ranges for prostate-specific antigen from a large community-based study. High-dose chemotherapy with autologous stem-cell transplantation for relapsed metastatic germ cell tumors The Alberta experience Hanbo Zhang, Nimira S. McMaster Institute of Urology at St. American Urological Association 3. PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: A prospective, multicenter clinical study. A four-kallikrein panel for the prediction of repeat prostate biopsy: Data from the European Randomized Study of Prostate Cancer screening in Rotterdam, Netherlands.